It was found that patients in the CALR high-expression group and IL1R1 high-expression group had shorter survival times, while those in the IFNB1 high-expression group and IFNB high-expression group had longer survival times (Figure 6C), consistent with the results of the TCGA-BLCA dataset (Figure 4A–D). The gene discussed is IL1R1; the disease is bladder transitional cell carcinoma.